We have detected that you are using an Ad Blocker.
PracticeUpdate is free to end users but we rely on advertising to fund our site. Please consider supporting PracticeUpdate by whitelisting us in your ad blocker.
We have sent a message to the email address you have provided, . If this email is not correct, please update your settings with your correct address.
The email address you provided during registration, , does not appear to be valid. Please update your settings with a valid address before to continue using PracticeUpdate.
Please provide your AHPRA Number to ensure that you are given the correct level of access to our site.
Published in Oncology

Journal Scan / Research · November 29, 2019

Ibrutinib as a Salvage Therapy After Allogeneic HCT for Chronic Lymphocytic Leukemia

Bone Marrow Transplantation

 

Additional Info

Bone Marrow Transplantation
Ibrutinib as a Salvage Therapy After Allogeneic HCT for Chronic Lymphocytic Leukemia
Bone Marrow Transplant 2019 Nov 07;[EPub Ahead of Print], M Michallet, P Dreger, M Sobh, et al

Further Reading